These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8822822)

  • 1. Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
    Brun-Pascaud M; Chau F; Rajagopalan-Levasseur P; Derouin F; Girard PM
    J Eukaryot Microbiol; 1996; 43(5):14S-15S. PubMed ID: 8822822
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis.
    Brun-Pascaud M; Chau F; Simonpoli AM; Girard PM; Derouin F; Pocidalo JJ
    J Infect Dis; 1994 Sep; 170(3):653-8. PubMed ID: 8077724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV: prevention of opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2003 Dec; (10):809-30. PubMed ID: 15555123
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiparasitic agent atovaquone.
    Baggish AL; Hill DR
    Antimicrob Agents Chemother; 2002 May; 46(5):1163-73. PubMed ID: 11959541
    [No Abstract]   [Full Text] [Related]  

  • 5. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients.
    Rodriguez M; Sifri CD; Fishman JA
    Clin Infect Dis; 2004 Apr; 38(8):e76-8. PubMed ID: 15095235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia.
    Hughes WT
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):247-52. PubMed ID: 7859136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice.
    Comley JC; Sterling AM
    Antimicrob Agents Chemother; 1995 Apr; 39(4):806-11. PubMed ID: 7785975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of infection due to Pneumocystis carinii.
    Fishman JA
    Antimicrob Agents Chemother; 1998 May; 42(5):995-1004. PubMed ID: 9593116
    [No Abstract]   [Full Text] [Related]  

  • 9. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections.
    Spencer CM; Goa KL
    Drugs; 1995 Jul; 50(1):176-96. PubMed ID: 7588086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
    Romand S; Della Bruna C; Farinotti R; Derouin F
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reinstituting trimethoprim--sulfamethoxazole in patients receiving atovaquone for Pneumocystis carinii pneumonia prophylaxis.
    James CW; McNelis KC; Szabo S
    Am J Health Syst Pharm; 2003 Aug; 60(15):1572-4. PubMed ID: 12951757
    [No Abstract]   [Full Text] [Related]  

  • 12. Criteria for use of atovaquone oral suspension in adult inpatients and outpatients.
    Goodwin SD; Fish DN
    Am J Health Syst Pharm; 1995 Nov; 52(21):2460-2. PubMed ID: 8564614
    [No Abstract]   [Full Text] [Related]  

  • 13. Rifabutin is active in murine models of toxoplasmosis.
    Araujo FG; Slifer T; Remington JS
    Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.
    Brun-Pascaud M; Rajagopalan-Levasseur P; Chau F; Bertrand G; Garry L; Derouin F; Girard PM
    Antimicrob Agents Chemother; 1998 May; 42(5):1068-72. PubMed ID: 9593128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
    Araujo FG; Suzuki Y; Remington JS
    Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis and therapy for Pneumocystis pneumonia--where are we?
    Masur H
    Infect Agents Dis; 1992 Oct; 1(5):270-8. PubMed ID: 1344666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model.
    Brun-Pascaud M; Chau F; Garry L; Jacobus D; Derouin F; Girard PM
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2067-70. PubMed ID: 8878582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV: prevention of opportunistic infections.
    Ioannidis J; Wilkinson D
    Clin Evid; 2005 Jun; (13):834-53. PubMed ID: 16135281
    [No Abstract]   [Full Text] [Related]  

  • 19. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study.
    Meyers B; Borrego F; Papanicolaou G
    Liver Transpl; 2001 Aug; 7(8):750-1. PubMed ID: 11510024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aerosolized synthetic surfactant, atovaquone, and the combination of these on murine Pneumocystis carinii pneumonia.
    Hughes WT; Sillos EM; LaFon S; Rogers M; Woolley JL; Davis C; Studenberg S; Pattishall E; Freeze T; Snyder G; Staton S
    J Infect Dis; 1998 Apr; 177(4):1046-56. PubMed ID: 9534981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.